Hims & Hers Health (NYSE:HIMS) Insider Soleil Boughton Sells 3,458 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 3,458 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $28.33, for a total value of $97,965.14. Following the completion of the sale, the insider directly owned 310,506 shares of the company’s stock, valued at approximately $8,796,634.98. This represents a 1.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Soleil Boughton also recently made the following trade(s):

• On Wednesday, August 19th, Soleil Boughton sold 25,111 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.55, for a total transaction of $691,808.05.

Hims & Hers Health Price Performance

HIMS opened at $27.77 on Friday. The firm has a market cap of $6.48 billion, a price-to-earnings ratio of -44.08 and a beta of 2.42. The company’s 50-day moving average price is $31.79 and its 200 day moving average price is $26.74. Hims & Hers Health, Inc. has a fifty-two week low of $13.74 and a fifty-two week high of $65.30. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The company had revenue of $753.21 million during the quarter, compared to analyst estimates of $698.90 million. Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.Hims & Hers Health’s quarterly revenue was up 38.2% on a year-over-year basis. During the same period in the prior year, the business earned $0.17 earnings per share.

Analyst Ratings Changes

A number of brokerages recently weighed in on HIMS. JPMorgan Chase & Co. cut their price objective on shares of Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 12th. Citigroup lowered their target price on shares of Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 11th. Morgan Stanley boosted their price target on shares of Hims & Hers Health from $21.00 to $28.00 and gave the stock an “equal weight” rating in a research report on Tuesday, August 11th. Zacks Research upgraded shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. Finally, Barclays lowered their price objective on shares of Hims & Hers Health from $39.00 to $35.00 and set an “overweight” rating on the stock in a research note on Friday, August 21st. Four equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $32.50.

Key Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers raised its 2026 revenue outlook after second-quarter revenue increased 38.2% year over year to $753.2 million, exceeding analyst expectations. The company’s growth drivers include weight-loss treatments, international expansion and artificial intelligence initiatives. HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite Loss
• Neutral Sentiment: Analyst sentiment remains cautious, with brokerages maintaining a consensus “Hold” rating. While some analysts cite weight-loss, international and AI momentum, margin pressure and uncertainty surrounding FDA oversight remain concerns. Analysts Have Conflicting Sentiments on These Healthcare Companies
• Negative Sentiment: Multiple law firms publicized a securities class-action lawsuit against Hims & Hers and certain executives. The case covers investors who purchased shares between August 4, 2025, and July 29, 2026, with a November 2, 2026 deadline to seek lead-plaintiff status. The repeated announcements amplified concerns about potential litigation costs, regulatory penalties and reputational damage. Kaplan Fox Class Action Announcement
• Negative Sentiment: The litigation follows allegations tied to an FTC complaint, including potentially deceptive privacy and billing practices. Allegations cited in the filings include sharing consumer health information with advertising platforms and charging for prescriptions shortly after intake submissions. These claims raise the risk of enforcement actions, fines and additional compliance costs, although they remain allegations.
• Negative Sentiment: An insider sold 3,458 shares for approximately $98,000 under a pre-arranged Rule 10b5-1 trading plan. The sale reduced the insider’s position by 1.1%, making it a relatively small and scheduled transaction, but it nevertheless adds a modest negative signal amid the broader legal concerns. Insider Trading Information

Institutional Trading of Hims & Hers Health

A number of hedge funds and other institutional investors have recently made changes to their positions in HIMS. Versant Capital Management Inc boosted its holdings in Hims & Hers Health by 801.2% during the second quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock worth $26,000 after buying an additional 665 shares in the last quarter. MassMutual Private Wealth & Trust FSB increased its holdings in shares of Hims & Hers Health by 70.0% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock valued at $27,000 after buying an additional 319 shares in the last quarter. Binnacle Investments Inc acquired a new stake in shares of Hims & Hers Health during the 3rd quarter valued at $28,000. Geneos Wealth Management Inc. bought a new stake in shares of Hims & Hers Health during the 1st quarter worth $30,000. Finally, Greenline Wealth Management LLC bought a new stake in shares of Hims & Hers Health during the 4th quarter worth $36,000. 63.52% of the stock is currently owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.